Novo Nordisk’s Weight Loss Drug, Wegovy, Reduces Risk of Heart Problems by 20%: Study
In a groundbreaking study published in the New England Journal of Medicine, researchers have found that Novo Nordisk’s weight loss drug, Wegovy, can significantly reduce the risk of serious heart problems in certain patients. The study, which involved over 17,600 adults with cardiovascular disease who were overweight or obese but did not have diabetes, was funded by Novo Nordisk.
According to the study’s results, Wegovy was found to reduce the risk of heart attacks by an impressive 28%, stroke by 8%, and death from any cause by 19%. These findings have led lead study author Dr. Michael Lincoff to describe the drug as a “game changer” for patients, as it provides another option for addressing weight-related conditions.
Wegovy, also known as semaglutide, was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and at least one weight-related condition. However, Novo Nordisk conducted the large drug trial to assess whether Wegovy had additional medical benefits beyond weight loss. The results from this study were similar to a previous study on Novo Nordisk’s drug Ozempic, which also reduced the risk of serious heart problems in people with diabetes.
As a result, Novo Nordisk has filed for a label update for Wegovy to include an indication for reducing the risk of major adverse cardiovascular events in patients with established cardiovascular disease and a BMI of at least 27 kg/m2. The company expects a decision from federal health regulators in 2024, and the FDA has granted priority review for the application.
The study’s findings provide hope for individuals with cardiovascular disease who struggle with their weight. With Wegovy’s potential to reduce heart attack and stroke risk, it could bring significant benefits to patients in the near future. With Novo Nordisk actively pursuing label updates and a potential FDA approval, the availability of Wegovy for reducing the risk of major adverse cardiovascular events may soon become a reality.
In conclusion, the study published in the New England Journal of Medicine highlights the potential of Novo Nordisk’s weight loss drug, Wegovy, to significantly reduce the risk of serious heart problems in certain patients. If approved, this could be a game-changer for individuals with cardiovascular disease, providing them with a new option for managing their weight and reducing their risk of adverse cardiovascular events.
